相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function
D. Chen et al.
ONCOGENE (2007)
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A. C. Joerger et al.
ONCOGENE (2007)
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Lauren F. Stevenson et al.
EMBO JOURNAL (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
Small molecule protein-protein inhibitors for the p53-MDM2 interaction
Anna S. Dudkina et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2007)
p53 in health and disease
Karen H. Vousden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Franck Toledo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy
Yipin Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction
Ke Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells
Llorenc Coll-Mulet et al.
BLOOD (2006)
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
TR Brummelkamp et al.
NATURE CHEMICAL BIOLOGY (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A global map of p53 transcription-factor binding sites in the human genome
CL Wei et al.
CELL (2006)
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
T Stühmer et al.
BLOOD (2005)
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry
R Nenutil et al.
JOURNAL OF PATHOLOGY (2005)
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro
M Krajewski et al.
NATURE MEDICINE (2005)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells
YL Yang et al.
CANCER CELL (2005)
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2
E Meulmeester et al.
MOLECULAR CELL (2005)
MDM2 is a central node in the p53 pathway: 12 years and counting
GL Bond et al.
CURRENT CANCER DRUG TARGETS (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor
ZN Demidenko et al.
CANCER RESEARCH (2004)
Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses
CP Rubbi et al.
EMBO JOURNAL (2003)
Inhibiting the p53-MDM2 interaction:: An important target for cancer therapy
P Chène
NATURE REVIEWS CANCER (2003)
Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
P Bertheau et al.
LANCET (2002)
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization
MY Li et al.
NATURE (2002)
Activation of p53 by roscovitine-mediated suppression of MDM2 expression
WG Lu et al.
ONCOGENE (2001)
分享论文
